ArticleAnnals of internal medicine2021
Comparative Effectiveness and Harms of Antibiotics for Outpatient Diverticulitis : Two Nationwide Cohort Studies.
Article in Annals of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Exploring effectiveness of Metronidazole, Bismuth, and Rifaximin in treating small intestinal bacterial overgrowth and irritable bowel syndrome: A systematic review.World journal of methodology · 2026Article
- Epidemiologic trends in pediatric urinary tract infections in United States emergency departments from 2016 to 2023.Clinical and experimental emergency medicine · 2026Article
- The Emerging Role of the Microbiota and Antibiotics in Diverticulitis Treatment.Clinics in colon and rectal surgery · 2025Review
- The Epidemiology of Diverticulitis.Clinics in colon and rectal surgery · 2025Review
- Management of Colonic Diverticular Disease in the Older Adult.Current gastroenterology reports · 2025Review
- Inferring Amoxicillin-Clavulanate Susceptibility From Ampicillin-Sulbactam Susceptibility Against Common Enterobacterales Species.Open forum infectious diseases · 2025Article
- Ternary-Emission Molecularly Imprinted Ratiometric Fluorescence Sensor and Kit for the Rapid and Visual Detection of Enrofloxacin.Biosensors · 2025Article
- Vaccine patterns among older adults with Guillain-Barré syndrome and matched comparators, 2006-2019.Journal of the American Geriatrics Society · 2024Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOutpatient diverticulitis is commonly treated with either a combination of metronidazole and a fluoroquinolone (metronidazole-with-fluoroquinolone) or amoxicillin-clavulanate alone. The U.S. Food and Drug Administration advised that fluoroquinolones be reserved for conditions with no alternative treatment options. The comparative effectiveness of metronidazole-with-fluoroquinolone versus amoxicillin-clavulanate for diverticulitis is uncertain.
objectiveTo determine the effectiveness and harms of metronidazole-with-fluoroquinolone versus amoxicillin-clavulanate for outpatient diverticulitis.
designActive-comparator, new-user, retrospective cohort studies.
settingNationwide population-based claims data on U.S. residents aged 18 to 64 years with private employer-sponsored insurance (2000 to 2018) or those aged 65 years or older with Medicare (2006 to 2015).
participantsImmunocompetent adults with diverticulitis in the outpatient setting.
interventionMetronidazole-with-fluoroquinolone or amoxicillin-clavulanate. MEASUREMENTS: 1-year risks for inpatient admission, urgent surgery, and
resultsIn MarketScan (IBM Watson Health), new users of metronidazole-with-fluoroquinolone ( LIMITATION: Residual confounding is possible, and not all harms associated with these antibiotics, most notably drug-induced liver injury, could be assessed.
conclusionTreating diverticulitis in the outpatient setting with amoxicillin-clavulanate may reduce the risk for fluoroquinolone-related harms without adversely affecting diverticulitis-specific outcomes. PRIMARY FUNDING SOURCE: National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.